Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Celldex Therapeutics, Inc. today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, is the subject of a poster presentation at the 2010 American Association for Cancer Research 101st Annual Meeting in Washington DC.

22 Apr 2010

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C.

19 Apr 2010

Scientists grow cultured neurons to investigate basic mechanisms of memory

In order to be able to understand complex organs such as the brain or the nervous system, simplified model systems are required. A group of scientists led by the Frankfurt brain researcher Erin Schuman has successfully developed a novel method to grow cultured neurons in order to investigate basic mechanisms of memory.

16 Apr 2010

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions, has signed a global SaaS CRM agreement with biopharmaceutical company UCB.

15 Apr 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Cegedim Dendrite signs five-year framework agreement with Pierre Fabre Laboratories

Cegedim Dendrite, the world leader in Customer Relationship Management solutions for the Pharmaceutical and Life Sciences industries, entered a five-year framework agreement with Pierre Fabre Laboratories, to strengthen and roll-out medical sales solutions to their international subsidiaries where Cegedim Dendrite solutions have not been implemented.

29 Mar 2010

Role Tregs play in therapeutic HIV vaccines

Like a skittish driver slamming the brakes, a special class of T cells may be limiting the effectiveness of therapeutic vaccines for HIV by slowing the immune system response too soon, report University of Pittsburgh health science researchers in the current issue of PLoS ONE. Their study, the first to look at the role of regulatory T cells in therapeutic HIV vaccines, may help researchers improve the efficacy of such vaccines by devising methods to circumvent the braking mechanism of these cells.

27 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time.

25 Mar 2010

Cegedim Dendrite's Sample Management Solutions launched in Europe CE

Cegedim Dendrite, the world’s leading provider of Pharmaceutical and Life-Sciences CRM solutions, today announced the launch of Sample Management Solutions, a new offering in Europe designed to help biopharmaceuticals companies comply with legal requirements associated with sample distribution.

24 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

New anti-tumour vaccine for mesothelioma shows promising results

A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

New data shows Valortim antibody enhances human T cell response to B. anthracis

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

25 Feb 2010

Enzyme can allow nerve cells in brain to grow and form complex networks: Study

Brain researcher Hiroshi Kawabe has discovered the workings of a process that had been completely overlooked until now, and that allows nerve cells in the brain to grow and form complex networks. The study shows that an enzyme which usually controls the destruction of protein components has an unexpected function in nerve cells: it controls the structure of the cytoskeleton and thus ensures that nerve cells can form the tree-like extensions that are necessary for signal transmission in the brain.

20 Feb 2010

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Celldex Therapeutics presents CDX-1127 antibody program at AACR Annual Meeting

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Scientists grow cultured neurons to investigate basic mechanisms of memory

Cegedim Dendrite announces global SaaS CRM agreement with UCB

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Cegedim Dendrite signs five-year framework agreement with Pierre Fabre Laboratories

Role Tregs play in therapeutic HIV vaccines

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

Cegedim Dendrite's Sample Management Solutions launched in Europe CE

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

New anti-tumour vaccine for mesothelioma shows promising results

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

New data shows Valortim antibody enhances human T cell response to B. anthracis

Enzyme can allow nerve cells in brain to grow and form complex networks: Study

Immunology eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in